Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players√Ę‚ā¨‚ĄĘ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Pneumoconiosis Market Research Report, By Type (Asbestosis, Berylliosis, Byssinosis, Coal Workers Pneumoconiosis, Silicosis), Cause (Organic Dusts, Non-Organic Substances), Therapy (Diagnosis, Treatment), End User (Hospital) - Forecast till 2030


ID: MRFR/Pharma/3218-HCR | 90 Pages | Author: Rahul Gotadki| April 2024

Pneumoconiosis Market Scenario:


The pneumoconiosis market is anticipated to reach USD 2,280.88 Million by 2030 at 9.40% CAGR during the forecast period 2022-2030.


Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.


Intended Audience



  • Biotechnological institutes

  • Pharmaceutical companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories


Figure 1:- Global Pneumoconiosis market share, by causes Pneumoconiosis Market

Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.


On the basis of types, the pneumoconiosis market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.


On the basis of causes, the pneumoconiosis market is categorised into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.


On the basis of therapy, the pneumoconiosis market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.


On the basis of end users, the pneumoconiosis market is segmented into hospital, clinics, and others. 


Regional Analysis


America dominates the pneumoconiosis market owing to large patient population. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is equals around 36.5 million adults in the United States currently smoke cigarettes. Increasing smoking population increases the possibility of causing the disease. Additionally, increasing awareness among the people regarding different diagnostic procedures and well-developed technology has also contributed to the growth of the market.


Europe is the second largest pneumoconiosis market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the market.


On the other hand, the Middle East & Africa has the least share in the pneumoconiosis market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by Middle East due to well-developed healthcare sector and huge healthcare expenditure. 


Research MethodologyPneumoconiosis Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for pneumoconiosis market


The key players for the pneumoconiosis market Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).


 

Report Attribute/Metric Details
  Market Size   2030: USD 2,280.88 Million
  CAGR   9.40% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Causes, Therapy, and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.)
  Key Market Opportunities Increasing geriatric population Increasing healthcare expenditure Strong encouragement from the government
  Key Market Drivers Increasing prevalence of pneumoconiosis Increasing smoking population Rising air pollution


Frequently Asked Questions (FAQ) :

Pneumoconiosis market is projected to grow at a 9.40% CAGR between 2022- 2030.

The Americas is expected to dominate the pneumoconiosis market.

Non-organic substances, organic dusts, and others are the major causes of pneumoconiosis.

Lack of long term treatment and certain side effects are factors that may limit the pneumoconiosis market growth.

Leading players profiled in the pneumoconiosis market include Bayer Cropscience Ltd. (U.S.), F. Hoffman La Roche AG (Germany), Svizera Healthcare (India), Pfizer (U.S.), Merck & Co. (U.S.), AstraZeneca (U.K), Abbott (U.S.), Novartis (Switzerland), Novo Nordisk (Denmark), Sanofi (France), Sunpharma (India), Sunpharma (India), and Abbott (US) Eli Lilly (U.S.).

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization